Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MCR141
MIFTS: 56

Mucormycosis

Categories: Infectious diseases, Neuronal diseases, Oral diseases, Rare diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Mucormycosis

About this section

MalaCards integrated aliases for Mucormycosis:

Name: Mucormycosis 12 74 52 58 3 15 17
Zygomycosis 12 74 52 58 3 32
Disseminated Mucormycosis 12 32

Characteristics:

Orphanet epidemiological data:

58
zygomycosis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
Anatomical: Respiratory diseases Oral diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:8485
MESH via Orphanet 44 D009091 D020096
UMLS via Orphanet 72 C0026718 C0043541
Orphanet 58 ORPHA73263
Sources

Summaries for Mucormycosis

About this section
CDC : 3 Mucormycosis (sometimes called zygomycosis) is a serious but rare fungal infection caused by a group of molds called mucormycetes. These fungi live throughout the environment, particularly in soil and in decaying organic matter, such as leaves, compost piles, or rotten wood.1 People get mucormycosis by coming in contact with the fungal spores in the environment. For example, the lung or sinus forms of the infection can occur after someone breathes in spores. These forms of mucormycosis usually occur in people who have health problems or take medicines that lower the body's ability to fight germs and sickness.3,6 Mucormycosis can also develop on the skin after the fungus enters the skin through a cut, scrape, burn, or other type of skin trauma.

MalaCards based summary : Mucormycosis, also known as zygomycosis, is related to aspergillosis and cavernous sinus thrombosis. An important gene associated with Mucormycosis is CSF3 (Colony Stimulating Factor 3), and among its related pathways/superpathways are Hematopoietic cell lineage and Innate Lymphoid Cells Differentiation. The drugs Voriconazole and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include sinuses, brain and lungs of immunocompromised people, and related phenotypes are vomiting and fatigue

Disease Ontology : 12 An opportunistic mycosis that results in fungal infection located in sinuses, located in brain, or located in lungs of immunocompromised people, has material basis in Mucorales molds.

Wikipedia : 74 Mucormycosis is any fungal infection caused by fungi in the order Mucorales. Generally, species in the... more...

Sources

Related Diseases for Mucormycosis

About this section

Diseases related to Mucormycosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 695)
# Related Disease Score Top Affiliating Genes
1 aspergillosis 30.8 IFNG CSF3 CSF2 CLEC7A CCR6 CABIN1
2 cavernous sinus thrombosis 30.8 RHNO1 CRP
3 neutropenia 30.7 IFNG CYP3A4 CSF3 CSF2 CRP
4 cellulitis 30.6 IFNG CRP CD4 CCR6
5 ethmoid sinusitis 30.5 RHNO1 CRP
6 orbital cellulitis 30.5 RHNO1 CRP
7 ecthyma 30.5 CSF3 CRP
8 fusariosis 30.4 CYP51A1 CSF3 CACNA1E
9 multiple cranial nerve palsy 30.4 RHNO1 CRP
10 leukemia, acute lymphoblastic 30.4 CYP3A4 CSF3 CSF2 CD4 CCR6
11 sphenoid sinusitis 30.3 RHNO1 CRP
12 pyelonephritis 30.3 IFNG CSF3 CRP
13 cranial nerve palsy 30.3 RHNO1 CRP CD4
14 pneumonia 30.2 IFNG CSF3 CSF2 CRP
15 aplastic anemia 30.2 IFNG CYP3A4 CSF3 CSF2 CD4
16 pyoderma 30.1 CSF3 CRP CCR6
17 cerebritis 30.1 RHNO1 CRP CD4
18 chronic graft versus host disease 30.1 IFNG CD4
19 immune deficiency disease 30.1 IFNG CYP3A4 CSF2 CD4 CCR6
20 panophthalmitis 30.0 IFNG CD4 B4GALNT2
21 gastroenteritis 30.0 IFNG CSF3 CSF2 CRP
22 actinomycosis 30.0 INS CRP CD4
23 pancytopenia 30.0 IFNG CSF3 CSF2 CRP CD4
24 pleural empyema 29.9 FLNC CRP CD4
25 appendicitis 29.9 IFNG CSF3 CRP
26 folliculitis 29.9 IFNG CD4 CCR6
27 common cold 29.9 FLNC CSF2 CD4 CCR6
28 histoplasmosis 29.9 IFNG CLEC7A CD4 CCR6
29 acquired immunodeficiency syndrome 29.9 IFNG CSF2 CRP CD4 CCR6
30 crohn's disease 29.8 IFNG CRP CD4 CCR6
31 meningitis 29.8 IFNG CSF3 CSF2 CRP
32 mediastinitis 29.8 RHNO1 INS CRP
33 pericarditis 29.8 IFNG CRP CD4
34 lung disease 29.8 INS IFNG CSF3 CSF2 CRP
35 nervous system disease 29.7 IFNG CSF2 CD4 CCR6
36 herpes zoster 29.7 IFNG CRP CD4 CCR6
37 malignant otitis externa 29.7 INS CRP
38 leprosy 3 29.7 IFNG CSF2 CD4 CCR6
39 neuroretinitis 29.7 CRP CD4
40 pharyngitis 29.7 CSF2 CRP CD4
41 sarcoidosis 1 29.7 IFNG CRP CD4 CCR6
42 candidiasis 29.7 IFNG CYP51A1 CSF2 CLEC7A CCR6 CARD9
43 chlamydia 29.6 IFNG CSF2 CRP
44 bacterial infectious disease 29.6 IFNG CSF3 CSF2 CRP CD4 CCR6
45 castleman disease 29.6 IFNG CSF3 CSF2 CRP
46 dysentery 29.6 CRP CD4 CCR6
47 chromoblastomycosis 29.5 CLEC7A CCR6 CARD9
48 otitis externa 29.4 RHNO1 CRP B4GALNT2
49 bacterial pneumonia 29.4 CSF3 CRP CD4 CCR6
50 endophthalmitis 29.4 CRP CD4 CARD9

Graphical network of the top 20 diseases related to Mucormycosis:



Diseases related to Mucormycosis
Sources

Symptoms & Phenotypes for Mucormycosis

About this section

Human phenotypes related to Mucormycosis:

58 (show top 50) (show all 76)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 vomiting 58 Occasional (29-5%)
2 fatigue 58 Frequent (79-30%)
3 renal insufficiency 58 Very rare (<4-1%)
4 fever 58 Frequent (79-30%)
5 sinusitis 58 Frequent (79-30%)
6 abnormal blistering of the skin 58 Occasional (29-5%)
7 hepatitis 58 Very rare (<4-1%)
8 pericarditis 58 Very rare (<4-1%)
9 abdominal pain 58 Occasional (29-5%)
10 pulmonary infiltrates 58 Occasional (29-5%)
11 gastrointestinal hemorrhage 58 Very rare (<4-1%)
12 osteolysis 58 Very rare (<4-1%)
13 cough 58 Frequent (79-30%)
14 chest pain 58 Occasional (29-5%)
15 ptosis 58 Very rare (<4-1%)
16 retinal detachment 58 Very rare (<4-1%)
17 hemoptysis 58 Occasional (29-5%)
18 diabetes mellitus 58 Occasional (29-5%)
19 abnormal cranial nerve morphology 58 Occasional (29-5%)
20 atelectasis 58 Occasional (29-5%)
21 proptosis 58 Very rare (<4-1%)
22 cellulitis 58 Occasional (29-5%)
23 periorbital edema 58 Occasional (29-5%)
24 epistaxis 58 Very rare (<4-1%)
25 myocarditis 58 Very rare (<4-1%)
26 endocarditis 58 Very rare (<4-1%)
27 neutropenia 58 Occasional (29-5%)
28 hematemesis 58 Occasional (29-5%)
29 hematochezia 58 Very rare (<4-1%)
30 headache 58 Occasional (29-5%)
31 mediastinal lymphadenopathy 58 Occasional (29-5%)
32 arterial thrombosis 58 Very rare (<4-1%)
33 premature birth 58 Occasional (29-5%)
34 encephalitis 58 Occasional (29-5%)
35 external ophthalmoplegia 58 Very rare (<4-1%)
36 hematological neoplasm 58 Occasional (29-5%)
37 pleural effusion 58 Occasional (29-5%)
38 diplopia 58 Very rare (<4-1%)
39 diarrhea 58 Occasional (29-5%)
40 pneumothorax 58 Occasional (29-5%)
41 thrombophlebitis 58 Very rare (<4-1%)
42 visual loss 58 Occasional (29-5%)
43 fasciitis 58 Occasional (29-5%)
44 pancreatitis 58 Very rare (<4-1%)
45 pustule 58 Occasional (29-5%)
46 peritonitis 58 Very rare (<4-1%)
47 loss of consciousness 58 Very rare (<4-1%)
48 ketoacidosis 58 Occasional (29-5%)
49 abnormality of the mediastinum 58 Occasional (29-5%)
50 gastritis 58 Occasional (29-5%)

GenomeRNAi Phenotypes related to Mucormycosis according to GeneCards Suite gene sharing:

26 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-101 9.68 CLEC7A
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-103 9.68 CLEC7A
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-128 9.68 CLEC7A
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 9.68 CLEC7A
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-147 9.68 CLEC7A CYP51A1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-15 9.68 CLEC7A
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.68 CD4
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-164 9.68 CLEC7A
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.68 CRP
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-202 9.68 CLEC7A
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-205 9.68 CLEC7A
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-209 9.68 CLEC7A
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-23 9.68 CYP51A1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-29 9.68 CLEC7A
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 9.68 CRP
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-54 9.68 CD4
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.68 CRP
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-79 9.68 CLEC7A
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.68 CLEC7A CRP
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-9 9.68 CLEC7A CYP51A1

MGI Mouse Phenotypes related to Mucormycosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.77 B4GALNT2 CACNA1E CARD9 CCR6 CD4 CLEC7A
2 immune system MP:0005387 9.4 B4GALNT2 CABIN1 CARD9 CCR6 CD4 CLEC7A
Sources

Drugs & Therapeutics for Mucormycosis

About this section

Drugs for Mucormycosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Voriconazole Approved Phase 4 137234-62-9 71616
2
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
3
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
4
Isavuconazole Approved, Investigational Phase 3 241479-67-4
5 Anti-Infective Agents Phase 3
6 Antifungal Agents Phase 3
7 Hormone Antagonists Phase 3
8 Cytochrome P-450 Enzyme Inhibitors Phase 3
9 Hormones Phase 3
10 Cytochrome P-450 CYP3A Inhibitors Phase 3
11
Amphotericin B Approved, Investigational Phase 2 1397-89-3 5280965 14956
12
Iron Approved, Experimental Phase 2 15438-31-0, 7439-89-6 27284 23925
13
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
14
Posaconazole Approved, Investigational, Vet_approved Phase 2 171228-49-2 147912
15 Amebicides Phase 2
16 Chelating Agents Phase 2
17 Iron Chelating Agents Phase 2
18 Antiprotozoal Agents Phase 2
19 Antiparasitic Agents Phase 2
20 Anti-Bacterial Agents Phase 2
21 Liposomal amphotericin B Phase 2

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 A Prospective, Randomized Trial Comparing the Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing Completed NCT01416025 Phase 4 Prospective TDM Arm
2 A Phase 3, Multi-center, Open Label Study to Evaluate Safety and Efficacy of AK1820 for Treatment of Adult Japanese Patients With Deep Mycosis Recruiting NCT03471988 Phase 3 AK1820;Voriconazole
3 Treatment of Rhino-Sinusal Mucormycosis Through Transnasal Endoscopic Surgery Extended to the Skull Base. Unknown status NCT02226705 Phase 2
4 The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study Completed NCT00419770 Phase 2 deferasirox;Placebo;Liposomal amphotericin B
5 AMBIZYGO: Efficacy of High Dose [10 mg/kg/j] Liposomal Amphotericin B (Ambisome)Efficacy in Initial Zygomycosis Treatment:Phase II Trial Completed NCT00467883 Phase 2 Liposomal Amphotericin B
6 Phase II Study of Safety, Tolerance, Efficacy, and Pharmacokinetics of Posaconazole (SCH 56592) for the Treatment of Invasive Fungal Infections in Immunocompromised Hosts Completed NCT00034671 Phase 2 Posaconazole oral suspension
7 A Phase II Trial of the Safety and Efficacy of Iron Reduction by Phlebotomy in Recipients of Hematopoietic Stem Cell Transplants Completed NCT00689182 Phase 2
8 A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects Active, not recruiting NCT03816176 Phase 2 Isavuconazonium sulfate;Isavuconazonium sulfate
9 Mucormycosis in ICU: A French Multicenter Cohort Study Unknown status NCT03387696
10 Systemic Fungal Infections in Intensive Care Unit Patients Unknown status NCT03292224
11 The Value of Real-Time Polymerase Chain Reaction (RT-PCR) Assay, Galactomannan and β-D-Glucan Detection (GM/G-Test) for Diagnosis of Invasive Fungal Infection (IFI) in Chinese Patients After Hematopoietic Stem Cell Transplantation (HSCT) Unknown status NCT00460330
12 Prospective Evaluation of a New Molecular Tool for Early Diagnosis of Mucormycosis Completed NCT02845934
13 Multicenter Observational Study on Epidemiology, Treatment and Outcome of Mucormycosis in India Completed NCT03429023
14 Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis Completed NCT00923832
15 Invasive Mould Infections in Indian ICUs - Descriptive Epidemiology, Management and Outcome Completed NCT02683642
16 Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU Not yet recruiting NCT04368221

Search NIH Clinical Center for Mucormycosis

Sources

Genetic Tests for Mucormycosis

About this section
Sources

Anatomical Context for Mucormycosis

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Mucormycosis:

19
Sinuses, Brain, Lungs Of Immunocompromised People

MalaCards organs/tissues related to Mucormycosis:

40
Lung, Skin, Brain, Bone, Liver, Kidney, Myeloid
Sources

Publications for Mucormycosis

About this section

Articles related to Mucormycosis:

(show top 50) (show all 4210)
# Title Authors PMID Year
1
Rhino-orbital-cerebral mucormycosis (ROCM) and associated cerebritis treated with adjuvant retrobulbar amphotericin B. 61
32551404 2020
2
A case of invasive pulmonary mucormycosis resulting from short courses of corticosteroids in a well-controlled diabetic patient. 61
32547914 2020
3
Risk factors for mortality in patients with pulmonary mucormycosis. 61
32304253 2020
4
Treatment of invasive fungal diseases in cancer patients-Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). 61
32236989 2020
5
A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. 61
31811914 2020
6
Posaconazole Serum Drug Levels Associated With Pseudohyperaldosteronism. 61
31403165 2020
7
Mucorales DNA detection in serum specimens for early diagnosis of mucormycosis. 61
32156450 2020
8
Successful treatment of disseminated granulomatous aspergillosis in an apparently immunocompetent host. 61
32576098 2020
9
Schizophyllum commune sphenoidal sinusitis as presentation of a non-Hodgkin Lymphoma. 61
32322473 2020
10
Mucormycosis due to Apophysomyces species complex- 25 years' experience at a tertiary care hospital in southern India. 61
31342074 2020
11
Burden of serious fungal infections in the Netherlands. 61
32297377 2020
12
GRP78 and Integrins Play Different Roles in Host Cell Invasion during Mucormycosis. 61
32487760 2020
13
In Vitro Evaluation of Radiolabeled Amphotericin B for Molecular Imaging of Mold Infections. 61
32393491 2020
14
Gastric ulcer due to mucormycosis in a critical patient. 61
32578998 2020
15
Otorhinolaryngological dysfunctions induced by chronic kidney disease in pre- and post-transplant stages. 61
32222803 2020
16
Case of mucormycosis of mandible after self-extraction of teeth incidentally detected to have chronic granulomatous disease: Case report and literature review. 61
32477856 2020
17
Rhizopus microsporus segmental enteritis in a cow. 61
32300518 2020
18
Gastrointestinal involvement of unusual Mucormycete Syncephalastrum racemosum in a diabetic patient with adenocarcinoma: rare case presentation with review of literature. 61
32506307 2020
19
Disseminated Mucormycosis Due to Saksenaea vasiformis Complex in an Immunocompetent Adult with Sustained Response to Posaconazole Treatment. 61
32279162 2020
20
Mucormycosis in the Middle East and North Africa: Analysis of the FungiScope® registry and cases from the literature. 61
32485012 2020
21
Microsatellite analysis of the population structure in Rhizopus arrhizus. 61
31965685 2020
22
Rhizoferrin Glycosylation in Rhizopus microsporus. 61
32570979 2020
23
Interlaboratory evaluation of Mucorales PCR assays for testing serum specimens: A study by the fungal PCR Initiative and the Modimucor study group. 61
32534456 2020
24
European confederation of medical mycology expert consult-An ECMM excellence center initiative. 61
32181546 2020
25
First Case of Rhinocerebral Mucormycosis Caused by Lichtheimia ornata, with a Review of Lichtheimia Infections. 61
32388712 2020
26
Mucormycosis in intensive care unit: surgery is a major prognostic factor in patients with hematological malignancy. 61
32514787 2020
27
Colonic Mucormycosis in Solid Organ Transplantation: Case Report and Review of the Literature (Colonic mucormycosis after DDLT). 61
32510728 2020
28
Rhino-Orbito-Cerebral Mucormycosis in Diabetic Disease Mucormycosis in Diabetic Disease. 61
32028364 2020
29
Diabetic versus non-diabetic rhino-orbito-cerebral mucormycosis. 61
32191363 2020
30
Positive quantitative PCR detecting Fusarium solani in a case of mixed invasive fungal disease due to Mucorales and Fusarium solani. 61
32024993 2020
31
Optimal management of acute kidney injury in critically ill patients with invasive fungal infections being treated with liposomal amphotericin B. 61
32404321 2020
32
A Retrospective Analysis of Invasive Fungal Diseases (IFD) of the Central Nervous System in Children With Lymphoid Malignancies. 61
31815886 2020
33
Aspergillus and Rhizopus Fungal Coinfection in a Patient With Multiple Myeloma. 61
32537269 2020
34
Evaluation of MucorGenius® mucorales PCR assay for the diagnosis of pulmonary mucormycosis. 61
32474046 2020
35
Pulmonary Mucormycosis: Risk Factors, Radiologic Findings, and Pathologic Correlation. 61
32196429 2020
36
Granulomatous Inflammation Presenting as a Pulmonary Artery Mass. 61
31563494 2020
37
An Unusual Case of Actinomucor elegans: A Challenging Diagnosis. 61
32409629 2020
38
Importance of the reversed halo sign for diagnosis of mucormycosis. 61
32359462 2020
39
CRISPR-Cas9-Based Mutagenesis of the Mucormycosis-Causing Fungus Lichtheimia corymbifera. 61
32466287 2020
40
Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus. 61
32205345 2020
41
Invasive mucormycosis during treatment for acute lymphoblastic leukaemia-successful management of two life-threatening diseases. 61
31410599 2020
42
Plant material (aeriferous parenchyma and sclereid cells) mimicking mucormycosis in sputum cytology. 61
32445261 2020
43
Liver Transplantation in Patients with Pretransplant Aspergillus Colonization: Is It Safe To Proceed? 61
32301905 2020
44
Deep fungal infections diagnosed by histology in Uganda: a 70-year retrospective study. 61
32242631 2020
45
A comparison of histomorphologic diagnosis with culture- and immunohistochemistry-based diagnosis of invasive aspergillosis and mucormycosis. 61
31973617 2020
46
Concomitant cerebral aspergillosis and mucormycosis in an immunocompetent woman treated with corticosteroids. 61
31713052 2020
47
Invasive Pulmonary Aspergillosis Due to Aspergillus awamori: Role of Calcium Oxalate Crystal Precipitation Mimicking Mucormycosis. 61
31741128 2020
48
Mucormycosis in a 40-year-old woman with diabetic ketoacidosis. 61
32312825 2020
49
Quantifying guideline adherence in mucormycosis management using the EQUAL score. 61
31876327 2020
50
Mucormycosis in children with haematological malignancies is a salvageable disease: a report from the Israeli Study Group of Childhood Leukemia. 61
31885080 2020
Sources

Variations for Mucormycosis

About this section
Sources

Expression for Mucormycosis

About this section
Search GEO for disease gene expression data for Mucormycosis.
Sources

Pathways for Mucormycosis

About this section

Pathways related to Mucormycosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Hematopoietic cell lineage 36
11.54 CSF3 CSF2 CD4
2
Innate Lymphoid Cells Differentiation 64
11.4 IFNG CD4 CCR6
3
Hematopoietic Stem Cells and Lineage-specific Markers 64
11.32 IFNG CSF3 CSF2 CD4
4
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.31 IFNG CSF2 CABIN1
5
Dendritic Cells Developmental Lineage Pathway 64
11.2 IFNG CSF2 CD4
6
Cytokines and Inflammatory Response 1
10.39 IFNG CSF3 CSF2 CD4
Sources

GO Terms for Mucormycosis

About this section

Cellular components related to Mucormycosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular membrane-bounded organelle GO:0043231 9.1 PPIG HSPA5 CYP51A1 CYP3A4 CYP2C19 CSF2

Biological processes related to Mucormycosis according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.91 INS IFNG CSF3 CSF2 CLEC7A
2 immune response GO:0006955 9.85 IFNG CSF3 CSF2 CD4 CCR6
3 positive regulation of gene expression GO:0010628 9.83 INS IFNG CSF2 CRP CLEC7A
4 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.52 CLEC7A CD4
5 negative regulation of amyloid-beta clearance GO:1900222 9.49 IFNG CYP51A1
6 negative regulation of blood vessel diameter GO:0097756 9.48 INS CRP
7 cellular response to granulocyte macrophage colony-stimulating factor stimulus GO:0097011 9.4 CSF2 CD4
8 positive regulation of respiratory burst GO:0060267 9.37 INS CLEC7A
9 heterocycle metabolic process GO:0046483 9.32 CYP3A4 CYP2C19
10 positive regulation of killing of cells of other organism GO:0051712 9.26 IFNG CLEC7A
11 monoterpenoid metabolic process GO:0016098 9.16 CYP3A4 CYP2C19
12 positive regulation of interleukin-23 production GO:0032747 8.96 IFNG CSF2
13 macrophage differentiation GO:0030225 8.8 IFNG CSF2 CD4

Molecular functions related to Mucormycosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 monooxygenase activity GO:0004497 9.33 CYP51A1 CYP3A4 CYP2C19
2 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.13 CYP51A1 CYP3A4 CYP2C19
3 enzyme binding GO:0019899 9.02 HSPA5 CYP3A4 CYP2C19 CSF3 CD4
Sources

Sources for Mucormycosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....